13 August
2024
Aptamer Group
plc
("Aptamer Group", "APTA" or
the "Company")
Result of General Meeting and Board
Changes
Aptamer Group (AIM:APTA), the developer of
novel Optimer® binders to enable innovation in the life sciences
industry, is pleased to announce that, further to the Company's
announcement on 24 July 2024 and subsequent announcement on 1
August 2024, at its General Meeting held today, all Resolutions
were passed.
Accordingly, all of the proposals set out in
the Company's circular dated 24 July 2024 (the "Circular") and the
announcement made on 1 August 2024 will proceed.
Board
Changes
With effect from Admission (scheduled
for 8:00 a.m. on 14 August 2024), the board will
comprise:
·
Dr Adam Hargreaves (Non-Executive
Chairman)
·
Dr Arron Tolley (Chief Executive
Officer)
·
Dr David Bunka (Chief Scientific
Officer)
·
Andrew Rapson (Chief Financial Officer)
The resignations of Stephen Hull
(Executive Chairman) and Dean Fielding (Non-Executive Director)
take effect from Admission.
The Company would like to take the
opportunity to thank Stephen and Dean for their contribution and
commitment over the last 12 months.
The Company is still to looking to
appoint another Non-Executive Director at the earliest
opportunity.
For further information, please
contact:
|
Aptamer Group plc
Dr Arron Tolley
|
+44 (0) 1904 217 404
|
|
SPARK Advisory Partners Limited -
Nominated Adviser
Andrew Emmott / Adam
Dawes
|
+44 (0) 20 3368 3550
|
|
Turner Pope Investments (TPI) Ltd -
Broker
James Pope / Andrew
Thacker
|
+44 (0) 20 3657 0050
|
Unless otherwise indicated,
capitalised terms in this announcement have the meaning given to
them in the Company's announcement dated 31 July 2023.
This announcement contains inside
information for the purposes of Article 7 of Regulation (EU) No
596/2014 as it forms part of UK domestic law by virtue of the
European Union (Withdrawal) Act 2018.
About Aptamer Group plc
Aptamer develops
custom affinity binders through its proprietary
Optimer® platform to enable new approaches in
therapeutics, diagnostics, and research applications. The
Company strives to deliver transformational solutions that meet the
needs of life science researchers and developers through the use of
its proprietary Optimer platform.
Optimer binders are oligonucleotide
affinity ligands that can function as an antibody
alternative. The global affinity ligand market is currently
worth over $170 billion. Optimer binders are engineered to
address many of the issues found with alternative affinity
molecules, such as antibodies, and offer new, innovative solutions
to bioprocessing, diagnostic and pharmaceutical
scientists.
Aptamer has successfully delivered
projects for global pharma companies, diagnostic development
companies, and research institutes covering a range of targets and
applications with the objective of establishing royalty-bearing
licenses. Through the unique Optimer technology and
processes, scientists and collaborators can make faster, more
informed decisions that support discovery and development across
the Life Sciences.
Further Disclosure regarding Andrew
Rapson
Andrew Rapson - Chief Financial
Officer (aged 42 years)
Andrew Rapson is a qualified
chartered accountant with an accountancy career spanning over 20
years. He has worked in an AIM environment for the last 9 years,
formerly as Head of Finance for Hunters Property plc before joining
Aptamer Group plc in 2022.
With effect from Second Admission,
Andrew Rapson will be interested in 3,000,000 ordinary Shares
representing 0.16% of the issued share capital.
Save as disclosed above, there are
no further disclosures in relation to the appointment of Andrew
Rapson pursuant to Schedule 2(g) of the AIM Rules for
Companies.